Compare Citius Pharmaceuticals Inc (CTXR) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Phillips 66 — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Phillips 66 trades at $195.46 (market cap $80.77B). The key difference: Phillips 66 is far larger — about 5517.1× Citius Pharmaceuticals Inc's market cap, and Phillips 66 pays a 2.52% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PSX | |
|---|---|---|
Market Cap | $14.64M | $80.77B |
Sector | Health | Energy |
52-Week High | $1.82 | $201.45 |
52-Week Low | $0.53 | $118.37 |
Enterprise Value | $10.86M | $102.74B |
Dividend Yield | — | 2.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Phillips 66 (PSX) trades at $198.29, up 5.27% with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 19.59, P/S of 0.6, and ROE of 14.75%, though revenue declined from $170B in 2022 to $132.38B in 2025. Recent earnings beats and consistent dividends of $1.27 quarterly support investor confidence amid refining margin strength.
Outlook remains positive with analyst consensus at Buy (57%) and $201.50 target, though risks include volatile oil prices, declining revenue trends, and high RSI suggesting overbought conditions. The refining sector benefits from Middle East tensions, but execution on cost control and margin stability will dictate near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
